Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Restructuring Reserve [Roll Forward]
Beginning balance	$ 55
Restructuring, impairment, and related charges, net	10	$ 52
Non-cash charges	(3)
Cash payments	(14)
Other	(5)
Ending balance	43
Operating Segments | U.S. Pharmaceutical
Restructuring Reserve [Roll Forward]
Beginning balance	18
Restructuring, impairment, and related charges, net	1	2
Non-cash charges	(1)
Cash payments	(3)
Other	(1)
Ending balance	14
Operating Segments | Prescription Technology Solutions
Restructuring Reserve [Roll Forward]
Beginning balance	5
Restructuring, impairment, and related charges, net	4	2
Non-cash charges	(1)
Cash payments	(1)
Other	(2)
Ending balance	5
Operating Segments | Medical-Surgical Solutions
Restructuring Reserve [Roll Forward]
Beginning balance	1
Restructuring, impairment, and related charges, net	3	2
Non-cash charges	0
Cash payments	(4)
Other	0
Ending balance	0
Operating Segments | International
Restructuring Reserve [Roll Forward]
Beginning balance	10
Restructuring, impairment, and related charges, net	1	6
Non-cash charges	(1)
Cash payments	(1)
Other	(1)
Ending balance	8
Corporate
Restructuring Reserve [Roll Forward]
Beginning balance	21
Restructuring, impairment, and related charges, net	1	$ 40
Non-cash charges	0
Cash payments	(5)
Other	(1)
Ending balance	16
Accrued Liabilities
Restructuring Reserve [Roll Forward]
Beginning balance	24
Ending balance	13
Other Non-Current Liabilities
Restructuring Reserve [Roll Forward]
Beginning balance	31
Ending balance	$ 30